Loading
Michael von Bergwelt is a haematologist who leads LMU's cell therapy and immuno-oncology programme.
Michael von Bergwelt is Director of the Department of Medicine III (Hematology and Oncology) at LMU Klinikum München. A haematologist, his specialisms are haematology, cell therapy and immunotherapy toxicity. He leads LMU's cell therapy and immuno-oncology programme, with research on CAR-T cell therapy, T-cell engaging bispecific antibodies and the management of immune-related toxicities. His department combines clinical haematology and oncology with the delivery of these newer immune therapies. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| Cytokine release syndrome | Journal for ImmunoTherapy of Cancer | 2018 |
| Advances in cancer immunotherapy 2019 – latest trends | Journal of Experimental & Clinical Cancer Research | 2019 |
| CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition | Blood | 2006 |
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific).
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific), CAR-T cell therapy.
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific), CAR-T cell therapy.
Shares Cytokine release syndrome (CRS), T-cell engagers (bispecific).